The two companies announced a three-year deal on March 18 for Integumen to manufacture and provide logistical support for Modern Water’s monitoring reagent consumables, which is expected to be worth a headline £3.12mln.
Integumen said the enlargement of its laboratories has begun with the ordering of new equipment, while the bacteria manufactured by Modern Water will be used to identify contamination in wastewater outlets from residential, hospital and municipal sewage treatment outflows that may contribute to the current public health crisis.
As previously announced, Integumen said that it will be investing £250,000 to rapidly expand its laboratories in York to 6,000 square feet to accelerate production of the bacteria reagent and maintain growth of its own Labskin product.
“We are now able to bring water contamination detection bacteria faster to the frontline environmental inspection teams, in crisis countries, where there is currently insufficient supply”, Integumen chief executive Gerard Brandon said in a statement.
"Integumen is in a strong position to provide the support for Modern Water and all their customers across the world through delivery of integrated engineering, scientific and real-time data analytical solutions in order to address this major societal and global problem in healthcare and the environment", he added.
Shares in Integumen jumped 7.6% to 1.1p in early deals on Monday.